Krystal Bio reported $119.2M in VYJUVEK revenue for Q2 2026, showcasing growing commercial traction. Maintaining a $1.1B cash balance, the company is on track for launches in Spain and Italy and advancing multiple registrations.
Krystal Bio reported $119.2M in VYJUVEK revenue for Q2 2026, showcasing growing commercial traction. Maintaining a $1.1B cash balance, the company is on track for launches in Spain and Italy and advancing multiple registrations.